NCT04560127

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Active, enrolled Phase 2 Last updated 10 July 2025

What this trial tests

Phase 2 trial testing Camrelizumab combination with Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 September 2020

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	23 September 2020
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

• Camrelizumab combination with Apatinib — full drug profile →

Conditions studied

• Radioactive Iodine-refractory Differentiated Thyroid Cancer — all drugs for Radioactive Iodine-refractory Differentiated Thyroid Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Radioactive Iodine-refractory Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
   Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
2. What is the status of immunotherapy in thyroid neoplasms?
   Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J. · · 2022 · cited 30× · PMID 35992118 · DOI 10.3389/fendo.2022.929091
3. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
   Silaghi H, Lozovanu V, Georgescu CE, Pop C, et al · · 2022 · cited 23× · PMID 35408830 · DOI 10.3390/ijms23073470
4. The Role of the Kinase Inhibitors in Thyroid Cancers.
   Cuomo F, Giani C, Cobellis G. · · 2022 · cited 18× · PMID 35631627 · DOI 10.3390/pharmaceutics14051040
5. Systemic treatments for radioiodine-refractory thyroid cancers.
   Chen P, Yao Y, Tan H, Li J. · · 2024 · cited 9× · PMID 39473507 · DOI 10.3389/fendo.2024.1346476
6. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.
   Li J, Zhang X, Mu Z, Sun D, et al · · 2022 · cited 9× · PMID 36003403 · DOI 10.3389/fimmu.2022.943916
7. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
   Cortas C, Charalambous H. · · 2023 · cited 7× · PMID 38255638 · DOI 10.3390/life14010022
8. Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.
   Zhang X, Sun D, Zhang Y, Mu Z, et al · · 2025 · PMID 41408254 · DOI 10.1186/s12916-025-04550-9